Helicobacter pylori infection vonoprazan, dual therapy, triple therapy, Helicobacter pylori eradication
Conditions
Interventions
Amoxicillin 500 mg 4 times daily and vonoprazan 20 mg twice daily, Amoxicillin 1 g twice daily, CLR-modified release (MR) 1 g once daily, and vonoprazan 20 mg twice daily,Amoxicillin 1 g twice daily,
14-day vonoprazan containing dual therapy,14-day vonoprazan triple therapy,7-day high-dose vonoprazan triple therapy,14-day vonoprazan triple therapy plus bismuth
Sponsors
Department of Medicine, Chulabhorn International College of Medicine (CICM) at Thammasat University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for patients were: patients between the ages of 18 and 70 years old diagnosed as non-ulcer dyspepsia based on the results of esophagogastroduodenoscopy (EGD) and had positive tests for H. pylori infection.
Exclusion criteria
Exclusion criteria: The exclusion criteria included patients who previously had received H. pylori treatment therapy; who had received antibiotics, bismuth, and/or PPIs/P-CAB within the preceding 4 weeks before the enrollment, had allergy to given drug in the regimens, previously had cardiac arrhythmia including QTc prolongation, who underwent gastric surgery or who were pregnant or breastfeeding women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter pylori eradication rate at least 4 weeks after treatment percentage | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse event at least 8 weeks after treatment Percentages | — |
Countries
Thailand
Contacts
Public ContactSarita Ratanaamornpin
Excellence Center in Digestive Diseases and Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Thammasat University Hospital, Pathumthani, Thailand
Outcome results
None listed